Related Experiment Video
Updated: Aug 29, 2025
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
Silencing RNA for MMPs May Be Utilized for Cardioprotection
Marta Banaszkiewicz1, Anna Krzywonos-Zawadzka1, Agnieszka Olejnik1
1Division of Clinical Chemistry and Laboratory Hematology, Department of Medical Laboratory Diagnostics, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211 A, 50-556 Wroclaw, Poland.
Abstract:
Ischemia/reperfusion (I/R) injury is accompanied by an increase of matrix metalloproteinase 2 (MMP-2) activity, which degrades heart contractile proteins. The aim of the study was to investigate the effect of MMP-2 small interfering RNA (MMP-2 siRNA) administration on I/R heart. Isolated rat hearts perfused by the Langendorff method were subjected to I/R in the presence or absence of MMP-2 siRNA. The hemodynamic parameters of heart function were monitored. Lactate dehydrogenase (LDH) activity was measured in coronary effluents. Activity and concentration of MMPs in the hearts were measured. Concentration of troponin I (TnI) in coronary effluents was examined as a target for MMP-2 degradation. Recovery of heart mechanical function was reduced after I/R; however, administration of MMP-2 siRNA resulted in restoration of proper mechanical function (p < 0.001). LDH activity was decreased after the use of MMP-2 siRNA (p = 0.02), providing evidence for reduced cardiac damage. Both MMP-2 and MMP-9 syntheses as well as their activity were inhibited in the I/R hearts after siRNA administration (p < 0.05). MMP-2 siRNA administration inhibited TnI release into the coronary effluents (p < 0.001). The use of MMP-2 siRNA contributed to the improvement of heart mechanical function and reduction of contractile proteins degradation during I/R; therefore, MMP-2 siRNA may be considered a cardioprotective agent.
Insights
Matrix metalloproteinase 2 (MMP-2) small interfering RNA (siRNA) administration improved heart function after ischemia/reperfusion (I/R) injury. MMP-2 siRNA reduced cardiac damage and contractile protein degradation, suggesting its cardioprotective potential.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Biochemistry
Background:
- Ischemia/reperfusion (I/R) injury elevates matrix metalloproteinase 2 (MMP-2) activity.
- MMP-2 degrades essential heart contractile proteins, contributing to cardiac dysfunction.
Purpose of the Study:
- To investigate the therapeutic effect of MMP-2 small interfering RNA (siRNA) on I/R-induced heart injury.
- To assess MMP-2 siRNA's impact on cardiac function, damage markers, and protein degradation.
Main Methods:
- Isolated rat hearts underwent I/R with or without MMP-2 siRNA administration.
- Hemodynamic parameters, lactate dehydrogenase (LDH) and troponin I (TnI) levels, and MMP activity were measured.
Main Results:
- MMP-2 siRNA administration restored heart mechanical function post-I/R (p < 0.001).
- Cardiac damage was reduced, evidenced by decreased LDH activity (p = 0.02).
- MMP-2 siRNA inhibited MMP-2 and MMP-9 synthesis and activity, and reduced TnI release (p < 0.001).
Conclusions:
- MMP-2 siRNA effectively improves cardiac mechanical function following I/R injury.
- MMP-2 inhibition by siRNA mitigates cardiac damage and contractile protein degradation.
- MMP-2 siRNA demonstrates significant cardioprotective potential in I/R models.
Related Concept Videos
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:22MicroRNAs